By analyzing the secretomes of 21 cancer cell lines derived from 12 cancer types, collapsin response mediator protein-2 (CRMP-2) was identified to be a potential CRC biomarker in the serums of 201 CRC patients and 210 healthy controls [42]. This evidence concerns the gene DPYSL2 and cancer.